The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Guideline for the Management of Nonmuscle Invasive Bladder Cancer (Stages Ta, T1, and Tis): 2007 Update
Abstract
You have accessJournal of UrologyAdult urology1 Dec 2007Guideline for the Management of Nonmuscle Invasive Bladder Cancer (Stages Ta, T1, and Tis): 2007 Update M. Craig Hall, Sam S. Chang, Guido Dalbagni, Raj Som Pruthi, John Derek Seigne, Eila Curlee Skinner, J. Stuart Wolf, and Paul F. Schellhammer M. Craig HallM. Craig Hall , Sam S. ChangSam S. Chang , Guido DalbagniGuido Dalbagni , Raj Som PruthiRaj Som Pruthi , John Derek SeigneJohn Derek Seigne , Eila Curlee SkinnerEila Curlee Skinner , J. Stuart WolfJ. Stuart Wolf , and Paul F. SchellhammerPaul F. Schellhammer View All Author Informationhttps://doi.org/10.1016/j.juro.2007.09.003AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail Introduction More than 60,000 new cases of bladder cancer are diagnosed each year in the US accounting for approximately 13,000 deaths annually.1 When initially diagnosed, most bladder cancers are nonmuscle invasive (also referred to as "superficial") – i.e., either noninvasive and confined to the mucosa or invading the lamina propria but not yet invading the detrusor muscle. In 1999, the AUA published a report on the Management of Non-Muscle-Invasive Bladder Cancer (Stages Ta, T1, and Tis) (AUA Guideline) produced by the AUA's Bladder Cancer Clinical Guideline Panel.2 The report provided an evidence-based guideline for the patient with nonmuscle invasive bladder cancer and included management standards, guidelines, and options based on the strength of evidence and expected amount of variation in patient preferences. Since 1999 the field of nonmuscle invasive bladder cancer has changed substantially with regard to the understanding of the molecular biology and clinical behavior of this heterogeneous disease. In addition, the growing body and quality of clinical research methodologies have improved during this period. The more recent publication of randomized controlled trials, the gold standard of treatment evaluation, has allowed the evaluation and comparison of various treatment modalities and has further verified the heterogeneous nature of this disease process. For these reasons, the AUA's PGC elected to update the initial report by appointing a panel to develop a new guideline for the management of nonmuscle invasive bladder cancer founded on evidence-based outcomes in the literature as well as expert opinion. Only topics with sufficient evidence on which to base conclusions have been addressed in this guideline. Index patients defined by the Panel will assist in determining appropriate therapy for different risk categories and are described later in this paper. The European Association of Urology also has supported recent efforts in the development of risk stratification schemes and has included them in Oosterlinck et al's Guidelines for TaT1 (Non-muscle Invasive) Bladder Cancer3 which are similar but not identical to the updated 2007 AUA Guideline. Whereas the complete AUA Guideline for the Management of Nonmuscle Invasive Bladder Cancer: (Stages Ta, T1, and Tis): 2007 Update which includes current information on epidemiology, risk stratification, tumor markers, modes of therapy, and bladder cancer characteristics is available online (http://www.auanet.org) and may answer many questions, this manuscript will focus on the actual treatment algorithm for the clinician and patient based on currently available modalities (table 1). Table 1. Current treatment alternatives Treatment Indication(s) TURBT • Any suspected urothelial carcinoma; can be sole treatment but only in nonmuscle invasive urothelial carcinoma4 Laser ablation therapy • Treatment of select lower- and upper-tract cancer5,6 • Treatment of low-grade papillary tumors • Not appropriate for new lesions prior to tumor staging/grading Conservative management (office fulguration or cystoscopic surveillance) • Low risk and recurrent nonmuscle invasive papillary bladder tumors • Well-documented history of low-grade Ta tumors7–9 Intravesical chemotherapy and immunotherapy (details provided below) • Perioperatively or postoperatively in an adjuvant fashion • To prevent recurrence following TURBT10–18 • Adjunctive therapy in Tis where diffuse tumor prevents complete resection19–22 Intravesical therapies Mechanism of action Immunomodulatory agents BCG • Inflammatory host response; release of cytokines • May be combined with interferons23–27 Interferons • Lymphocyte activation; cytokine release; phagocyte stimulation • Antiproliferative actions • Antiangiogenic19,23 Chemotherapeutic agents Thiotepa • Alkylating agent; cross-links nucleic acids28 Mitomycin C • Antibiotic; inhibits DNA synthesis10–12 Doxorubicin, epirubicin, valrubicin • Intercalating agents; inhibits DNA synthesis29–31 Gemcitabine • Deoxycytidine analog; inhibits DNA synthesis32–36 Methodology The methodology of this guideline update was similar to that used in the previous guideline. The intention was to determine the impact of the various av
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Radical Cystectomy in the Treatment of Invasive Bladder Cancer: Long-Term Results in 1,054 Patients
Stein, J. P., Lieskovsky, G., Cote, R., Groshen, S., Feng, A.-C., Boyd, S., Skinner, E., Bochner, B., Thangathurai, D., Mikhail, M., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.3.666 · Cited by 3,530
Self-citationWalsh, M. P. C. (1986) · Cited by 3,471
Sylvester, R. J., van der Meijden, A. P. M., Oosterlinck, W., Witjes, J. A., Bouffioux, C., Denis, L., Newling, D. W. W., & Kurth, K. (2006) · European Urology · doi:10.1016/j.eururo.2005.12.031 · Cited by 3,013
von der Maase, H., Hansen, S. W., Roberts, J. T., Dogliotti, L., Oliver, T., Moore, M. J., Bodrogi, I., Albers, P., Knuth, A., Lippert, C. M., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.17.3068 · Cited by 2,279
SYLVESTER, R. J., van der MEIJDEN, A. P. M., & LAMM, D. L. (2002) · Journal of Urology · doi:10.1016/s0022-5347(05)64273-5 · Cited by 1,312
SYLVESTER, R. J., OOSTERLINCK, W., & van der MEIJDEN, A. P. M. (2004) · Journal of Urology · doi:10.1097/01.ju.0000125486.92260.b2 · Cited by 743
BÖHLE, A., JOCHAM, D., & BOCK, P. R. (2003) · Journal of Urology · doi:10.1016/s0022-5347(05)64043-8 · Cited by 616
Böhle, A., & Bock, P. R. (2004) · Urology · doi:10.1016/j.urology.2003.11.049 · Cited by 465
SYLVESTER, R. J., van der MEIJDEN, A. P. M., WITJES, J. A., & KURTH, K. (2005) · Journal of Urology · doi:10.1097/01.ju.0000162059.64886.1c · Cited by 385
Urothelial Tumors of the Urinary Tract
Wj, C., & Catàlona, W. J. (1992) · Cited by 373
Oosterlinck, W., Kurth, K. H., Schröder, F., Bultinck, J., Hammond, B., Sylvester, R., & Embers of the European Organization for Research and Treatment of Cancer Genitourinary Group (1993) · Journal of Urology · doi:10.1016/s0022-5347(17)36198-0 · Cited by 361
Shelley, M. D., Wilt, T. J., Court, J., Coles, B., Kynaston, H., & Mason, M. D. (2004) · BJU International · doi:10.1111/j.1464-410x.2003.04655.x · Cited by 342
Han, R. F., & Pan, J. G. (2006) · Urology · doi:10.1016/j.urology.2005.12.014 · Cited by 340
Comprehensive Textbook of Genitourinary Oncology
Vogelzang, N. J. (2012) · Cited by 339
Tolley, D. A., Parmar, M. K. B., Grigor, K. M., Lallemand, G., & The Medical Research Council Superficial Bladder Cancer Working Party (1996) · Journal of Urology · doi:10.1016/s0022-5347(01)66226-8 · Cited by 323
Shelley, M. D., Kynaston, H., Court, J., Wilt, T. J., Coles, B., Burgon, K., & Mason, M. D. (2001) · BJU International · doi:10.1046/j.1464-410x.2001.02306.x · Cited by 313
Methods to Improve Efficacy of Intravesical Mitomycin C: Results of a Randomized Phase III Trial
Au, J. L.-S., Badalament, R. A., Wientjes, M. G., Young, D. C., Warner, J. A., Venema, P. L., Pollifrone, D. L., Harbrecht, J. D., Chin, J. L., Lerner, S. P., et al. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.8.597 · Cited by 308
Joudi, F. N., Smith, B. J., & O’Donnell, M. A. (2006) · Urologic Oncology: Seminars and Original Investigations · doi:10.1016/j.urolonc.2005.11.026 · Cited by 245
Comprehensive Textbook of Genitourinary Oncology
Burch, P. A. (1997) · Mayo Clinic Proceedings · doi:10.4065/72.4.384 · Cited by 235
Smith, J. A. J., Labasky, R. F., Cockett, A. T. �., Fracchia, J. A., Montie, J. E., & Rowland, R. G. (1999) · PubMed · Cited by 215
SMITH, J. A., LABASKY, R. F., COCKETT, A. T. K., FRACCHIA, J. A., MONTIE, J. E., & ROWLAND, R. G. (1999) · Journal of Urology · doi:10.1016/s0022-5347(05)68208-0 · Cited by 197
Krege, S., Giani, G., Meyer, R., Otto, T., & Rubben, H. (1996) · Journal of Urology · doi:10.1016/s0022-5347(01)65673-8 · Cited by 195
De Boer, E. C., De Jong, W. H., Steerenberg, P. A., Aarden, L. A., Tetteroo, E., De Groot, E. R., Van der Meijden, A. P. M., Vegt, P. D. J., Debruyne, F. M. J., & Ruitenberg, E. J. (1992) · Cancer Immunology, Immunotherapy · doi:10.1007/bf01741551 · Cited by 193
Carcinoma in Situ of the Bladder
Hudson, M. A., & Herr, H. W. (1995) · Journal of Urology · doi:10.1016/s0022-5347(01)67650-x · Cited by 192
Bouffioux, C., Kurth, K. H., Bono, A., Oosterlinck, W., Kruger, C. B., De Pauw, M., & Sylvester, R. (1995) · Journal of Urology · doi:10.1016/s0022-5347(01)67608-0 · Cited by 174
Huncharek, M. S., McGarry, R. C., & Kupelnick, B. (2001) · PubMed · Cited by 131
Zincke, H., Utz, D. C., Taylor, W. F., Myers, R. P., & Leary, F. J. (1983) · The Journal of Urology · doi:10.1016/s0022-5347(17)52205-3 · Cited by 126
Bouffioux, C., Kurth, K. H., Bono, A., et al. (1995) · Radboud Repository (Radboud University) · Cited by 123
EAU Guidelines on the Diagnosis and Treatment of Urothelial Carcinoma in Situ
van der Meijden, A. P. M., Sylvester, R. J., Oosterlinck, W., Solsona, E., Boehle, A., Lobel, B., & Rintala, E. (2005) · European Urology · doi:10.1016/j.eururo.2005.05.011 · Cited by 122
Watchful Waiting Policy in Recurrent Ta G1 Bladder Tumors
Gofrit, O. N., Pode, D., Lazar, A., et al. (2006) · European Urology · doi:10.1016/j.eururo.2005.12.029 · Cited by 119
Intravesical chemotherapy prophylaxis in primary superficial bladder cancer
Huncharek, M. S., Geschwind, J.-F. H., Witherspoon, B. J., McGarry, R. C., & Adcock, D. F. (2000) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(99)00203-6 · Cited by 100
A Bayesian Method for Synthesizing Evidence: The Confidence Profile Method
Eddy, D. M., Hasselblad, V., & Shachter, R. D. (1990) · International Journal of Technology Assessment in Health Care · doi:10.1017/s0266462300008928 · Cited by 98
The Confidence Profile Method: A Bayesian Method for Assessing Health Technologies
Eddy, D. M. (1989) · Operations Research · doi:10.1287/opre.37.2.210 · Cited by 93
May, M., Nitzke, T., Helke, C., Vogler, H., & Hoschke, B. (2004) · Scandinavian Journal of Urology and Nephrology · doi:10.1080/00365590410029141 · Cited by 79
Bouffioux, C., Kurth, K. H., Bono, A. V., et al. (1995) · The Journal of Urology · doi:10.1097/00005392-199503001-00012 · Cited by 78
BCG immunotherapy for transitional-cell carcinoma in situ of the bladder.
Lamm, D. L. (1995) · PubMed · Cited by 55
Phase 1/2 Study of Intravesical Epirubicin in Patients with Carcinoma in Situ of the Bladder
Kurth, K., van der Vijgh, W. J. F., ten Kate, F. J. W., Bogdanowicz, J. F. A. T., Carpentier, P. J., & van Reyswoud, I. (1991) · The Journal of Urology · doi:10.1016/s0022-5347(17)38152-1 · Cited by 35
Cited by
Kamat, A. M., Hahn, N. M., Efstathiou, J. A., Lerner, S. P., Malmström, P.-U., Choi, W., Guo, C. C., Lotan, Y., & Kassouf, W. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30512-8 · Cited by 1,421
The mechanism of action of BCG therapy for bladder cancer--a current perspective
Redelman-Sidi, G., Glickman, M. S., & Bochner, B. H. (2014) · Nature Reviews Urology · doi:10.1038/nrurol.2014.15 · Cited by 729
Panebianco, V., Narumi, Y., Altun, E., Bochner, B. H., Efstathiou, J. A., Hafeez, S., Huddart, R., Kennish, S., Lerner, S., Montironi, R., et al. (2018) · European Urology · doi:10.1016/j.eururo.2018.04.029 · Cited by 658
Kim, W.-J., Kim, E.-J., Kim, S.-K., Kim, Y.-J., Ha, Y.-S., Jeong, P., Kim, M.-J., Yun, S.-J., Lee, K., Moon, S.-K., et al. (2010) · Molecular Cancer · doi:10.1186/1476-4598-9-3 · Cited by 398
Urothelial Carcinoma of the Bladder and the Upper Tract: Disparate Twins
Green, D. A., Rink, M., Xylinas, E., Matin, S. F., Stenzl, A., Roupret, M., Karakiewicz, P. I., Scherr, D. S., & Shariat, S. F. (2013) · Journal of Urology · doi:10.1016/j.juro.2012.05.079 · Cited by 362
Metadata
- Authors
- Hall, M. C., Chang, S. S., Dalbagni, G., Pruthi, R. S., Seigne, J. D., Skinner, E. C., Wolf, J. S., & Schellhammer, P. F.
- Venue
- Journal of Urology
- Published
- 2007-12
- Volume
- 178
- Issue
- 6
- Pages
- 2314-2330
- ISSN
- 0022-5347 (ISSN-L)
- 1527-3792
- OpenAlex
- W2155829623
- Cited by
- 830
- References
- 37
- FWCI
- 45.56
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.